Assyro AI

Purple Book product · Interchangeable

Steqeyma

ustekinumab-stba

351(k) InterchangeableBLA 761338RxLicensed CELLTRION, Inc.

At a glance

Dec 17, 2024

Approved

Interchangeable

License type

Rx

Marketing

No

Patents listed

Key dates

  1. Approval

    Approval date of this BLA submission.

    Dec 17, 2024

    1 yr 6 mo ago

  2. Today

Pharmaceutical detail

Strength

45MG/0.5ML

Dosage form

Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

1996

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

Biosimilar of ustekinumab (Stelara)

Patent list (12)

Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
6,902,734Sep 25, 20232 yr 9 mo agoFDA
6,902,734Sep 25, 20232 yr 9 mo agoFDA
8,852,889Jul 06, 2032in 6 yr 2 moFDA
8,852,889Jul 06, 2032in 6 yr 2 moFDA
9,475,858Jul 06, 2032in 6 yr 2 moFDA
9,475,858Jul 06, 2032in 6 yr 2 moFDA
9,217,168Mar 14, 2033in 6 yr 11 moFDA
9,217,168Mar 14, 2033in 6 yr 11 moFDA
9,663,810Mar 14, 2033in 6 yr 11 moFDA
9,663,810Mar 14, 2033in 6 yr 11 moFDA
10,961,307Sep 24, 2039in 13 yr 6 moFDA
10,961,307Sep 24, 2039in 13 yr 6 moFDA

Taxonomy and ontology

11 terms

center

Center for Drug Evaluation and Research

center · CDER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(k) Interchangeable

blaType · 351(k) Interchangeable

application pathway

Section 351(k) Biosimilar or Interchangeable

blaType · 351(k)

product role

Interchangeable Biologic

blaType · Interchangeable

marketing status

Prescription

marketingStatus · Rx

licensure status

Licensed

licensure · Licensed

route

Subcutaneous

routeOfAdministration · Subcutaneous

dosage form

Injection

dosageForm · Injection

source kind

Monthly Download

sourceKind · monthly_download

  • Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
  • Food and Drug Administrationsource forMonthly Download
  • Biologics License Applicationparent ofSection 351(a) Biologic
  • Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
  • Section 351(k) Biosimilar or Interchangeablemaps to351(k) Biosimilar
  • Section 351(k) Biosimilar or Interchangeablemaps to351(k) Interchangeable

Source provenance

Source kind · Monthly download
Checked May 28, 2026
FDA release · April 2026
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.